As the world’s leading cancer research professionals arrived at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona on Friday, they were given a reminder of some of the remaining challenges that lie ahead in their field. 13 September 2024
US pharma giant Pfizer reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial guidance provided on December 17, 2024. 4 February 2025
AdvanCell announced the successful completion of an oversubscribed $112 million (US) Series C financing, making it the only Australian radiopharma company that has cash to burn. 4 February 2025
German biotech Akribion Therapeutics has emerged from stealth with 8 million euros ($9 million) in seed funding to accelerate the development of its novel RNA-guided precision medicines. 4 February 2025
Eleva, a German biopharmaceutical company, and 3PBIOVIAN, a global contract development and manufacturing organization (CDMO), have announced a strategic partnership to enhance the production of Eleva's pipeline products. 4 February 2025
Sionna Therapeutics hopes to raise $150 million and secure a market capitalization of about $692 million in an initial public offering (IPO). 4 February 2025
Japan’s ASKA Pharmaceutical Holdings announced it has decided to acquire additional shares of Vietnam-based Ha Tay Pharmaceutical (Hataphar). 4 February 2025
I-Mab has laid off almost a third of its employees as part of a restructuring effort, the company disclosed in a recent filing with the US Securities and Exchange Commission. 3 February 2025
US mRNA specialist Moderna demonstrated substantial R&D investment and progress in the UK, two years since signing its strategic partnership with the UK government, at a milestone event at the Harwell Campus in Oxfordshire. 3 February 2025
The market for Parkinson’s disease (PD) drugs across the seven major geographies (7MM; USA, France, Germany, Italy, UK and Japan) is projected to grow at a compound annual growth rate (CAGR) of 8.9% from $3.4 billion in 2023 to $7.9 billion in 2033. 3 February 2025
Japan’s Eisai and US partner Biogen have announced today update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab (trade name Leqembi) as a treatment for early mild cognitive impairment due to Alzheimer’s disease (AD) and mild AD) in the European Union. 3 February 2025
Japan’s ASKA Pharmaceutical Holdings announced it has decided to acquire additional shares of Vietnam-based Ha Tay Pharmaceutical (Hataphar). 4 February 2025